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RESEARCH
Effect of calcium supplements on risk of myocardial
infarction and cardiovascular events: meta-analysis
Mark J Bolland, senior research fellow,1 Alison Avenell, clinical senior lecturer,2 John A Baron, professor,3
Andrew Grey, associate professor,1 Graeme SMacLennan, senior research fellow,2 Greg D Gamble, research
fellow,1 Ian R Reid, professor1
ABSTRACT
Objective To investigate whether calcium supplements
increase the risk of cardiovascular events.
Design Patient level and trial level meta-analyses.
Data sourcesMedline, Embase, and Cochrane Central
Register of Controlled Trials (1966-March 2010),
reference lists of meta-analyses of calcium supplements,
and two clinical trial registries. Initial searches were
carried out in November 2007, with electronic database
searches repeated in March 2010.
Study selection Eligible studies were randomised,
placebo controlled trials of calcium supplements
(≥500 mg/day), with 100 or more participants of mean
agemore than 40 years and study durationmore than one
year. The lead authors of eligible trials supplied data.
Cardiovascular outcomeswere obtained fromself reports,
hospital admissions, and death certificates.
Results 15 trials were eligible for inclusion, five with
patient level data (8151 participants, median follow-up
3.6 years, interquartile range 2.7-4.3 years) and 11 with
trial level data (11921 participants, mean duration
4.0 years). In the five studies contributing patient level
data, 143 people allocated to calcium had a myocardial
infarction compared with 111 allocated to placebo
(hazard ratio 1.31, 95% confidence interval 1.02 to 1.67,
P=0.035). Non-significant increases occurred in the
incidence of stroke (1.20, 0.96 to 1.50, P=0.11), the
composite end point of myocardial infarction, stroke, or
sudden death (1.18, 1.00 to 1.39, P=0.057), and death
(1.09, 0.96 to 1.23, P=0.18). The meta-analysis of trial
level data showed similar results: 296 people had a
myocardial infarction (166 allocated to calcium, 130 to
placebo), with an increased incidence of myocardial
infarction in those allocated to calcium (pooled relative
risk 1.27, 95% confidence interval 1.01 to 1.59,
P=0.038).
Conclusions Calcium supplements (without
coadministered vitamin D) are associated with an
increased risk of myocardial infarction. As calcium
supplements are widely used these modest increases in
risk of cardiovascular disease might translate into a large
burden of disease in the population. A reassessment of
the role of calcium supplements in the management of
osteoporosis is warranted.
INTRODUCTION
Osteoporosis is a major cause of morbidity and mor-
tality in older people.1 Calcium supplements margin-
ally reduce the risk of fracture,23 and most guidelines
recommend adequate calcium intake as an integral
part of the prevention or treatment of osteoporosis.4 5
Consequently, calcium supplements are commonly
used by people over the age of 50. Observational stu-
dies suggest that high calcium intake might protect
against vascular disease,6-8 and the findings are consis-
tent with those of interventional studies of calcium sup-
plements that show improvement in somevascular risk
factors.9-11 In contrast, calcium supplements accelerate
vascular calcification and increasemortality in patients
with renal failure, in both dialysis and predialysis
populations.12-14 Furthermore, a five year randomised
controlled trial of calcium supplements in healthy
older women, in which cardiovascular events were
prespecified as secondary end points, recently
reported possible increases in rates of myocardial
infarction and cardiovascular events in women allo-
cated to calcium.15 16 We carried out a meta-analysis
of cardiovascular events in randomised trials of cal-
cium supplements.
METHODS
InNovember 2007we searchedMedline, Embase, and
the Cochrane Central Register of Controlled Trials for
randomised placebo controlled trials of calcium sup-
plements, using the terms “calcium”, “randomised
controlled trial”, and “placebo” as text words, and cor-
respondingMeSH terms (full details are available from
the authors). We searched for studies in the reference
lists of meta-analyses published between 1990 and
2007 of the effect of calcium supplements on bone den-
sity, fracture, colorectal neoplasia, and blood pressure,
and in two clinical trial registries (ClinicalTrials.gov
and Australian New Zealand Clinical Trials Registry).
No language restrictions were applied. In March 2010
we updated the searches of the electronic databases
(Medline: January 1966-March 2010, Embase: Janu-
ary 1980-March 2010, Central Register of Controlled
Trials: first quarter 2010).
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Study selection
We included studies if they were randomised, double
blind, placebo controlled trials; elemental calciumwas
administered at a dose of ≥500 mg/day; the partici-
pants’ mean age at baseline was more than 40 years;
100 or more participants were randomised; partici-
pants of either sex were studied; and the trial duration
was more than one year.
We excluded trials concerning calcium and vitamin
D given together with a placebo comparator (trials
were only eligible if vitamin D was given to both inter-
vention and control groups, because vitaminD supple-
mentation has been associated with decreased
mortality17); trials in which calcium was administered
in the form of dietary modification or a complex nutri-
tional supplement; and trials in which most partici-
pants had a major systemic disease other than
osteoporosis.
Search results
One investigator (MB) carriedout the initial search and
two investigators (AG and MB) independently
reviewed all potentially relevant studies. Overall, 190
potentially relevant reports of studies were identified
from the initial searches, but only 15 studies were eli-
gible for analysis.15 16 18-33 Thirteen studies compared
calcium supplements with placebo,15 16 18-27 29 31-33 one
study had a 2×2 factorial design allowing comparison
of calcium with placebo and calcium plus vitamin D
with vitamin D,28 and one study compared calcium
plus alendronate with alendronate.30
Data description
We invited the lead author of each eligible study to
provide patient level data on cardiovascular events
that occurred during the study irrespective of whether
the participant was still taking the trial drug. When
such data were not available we requested summary
data at trial level. We obtained patient level data on
cardiovascular outcomes for five studies, and partially
complete trial level data for six. No data were available
for four studies because the original records were no
longer available and cardiovascular events were not
previously reported,18 20 or no cardiovascular data
were available.23 26 Thus, patient level data on cardio-
vascular outcomes were available for 63% of partici-
pants in the 15 eligible studies, complete trial level
data for 85% of participants, and at least partially com-
plete trial level data for 93% of participants. Basic
demographic and other trial related data were either
supplied by the lead authors (or nominated deputies)
or extracted from the original publication by an inves-
tigator (MB).
Ascertainment of cardiovascular events
We considered a myocardial infarction to have
occurred when either of the terms “myocardial infarc-
tion” or “heart attack”, or code 410 (international clas-
sification of diseases, ninth revision), was used to
describe the event. A stroke was considered to have
occurred when any of the terms “stroke”, “cerebral
infarction”, “intracerebral hemorrhage”, “subarach-
noid hemorrhage”, or “cerebrovascular accident”, or
any of the ICD-9 codes 430, 431, 433, 434 were used
to describe the event.We considered a sudden death to
have occurred when the term “sudden death” or the
ICD-9 code 798 was used to describe the event.
Five studies contributed patient level data on cardio-
vascular events. For one study,21 22 self reports of unad-
judicated events were supplied. Another study28
supplied self reports of hospital admissions and cause
of death from death certificates. Each event was then
independently adjudicated by two physicians blinded
to the treatment allocation of the participants (MB,
AG), and any disagreements were resolved by consen-
sus. For another study,25 verified events from hospital
discharge data were supplied along with causes of
deaths from death certificates. The causes of death
were again independently adjudicated. For two
studies,15 33 data from self reports, hospital admissions,
and death certificates were independently adjudicated
by a cardiologist or neurologist, as previously
described.16 For six studies contributing trial level
data, all data on cardiovascular events were supplied
by the lead authors and were obtained from physician
reported cause of death in one study27 and a combina-
tion of self reports and hospital discharge data in five
studies.19 24 29-32
End points
The prespecified primary end points were time to first
myocardial infarction, time to first stroke, and time to
first event for the composite end point of myocardial
infarction, stroke, or sudden death. The secondary end
point was time to death (all cause mortality).
Statistical analysis
In trials with patient level data, we analysed each end
point using a Cox proportional hazards model, with a
dummy coded variable representing each study in the
model, and we reported the hazard ratio, with 95%
confidence interval, and number needed to treat. The
assumption of proportional hazards was explored by
Reports of studies identified by initial search (n=11 363)
Reports of potentially relevant studies
identified and screened for retrieval (n=190)
28 reports of 15 studies eligible for inclusion
Reports of studies excluded (n=162):
  Study size (n=111)
  Duration ≤12 months (n=30)
  Study design (n=21)
Fig 1 | Flowchart of studies. Initial search was in November
2007: 9358 reports were identified, 173 reports of potentially
relevant studies retrieved, 150 reports excluded, and 23
reports of 15 individual studies identified. Search was
updated in March 2010: a further 2005 reports were identified
and 17 reports retrieved but no new studies identified
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carrying out a test for proportionality of the interaction
between variables included in the model and the loga-
rithm of time. For a small number of events (<10%) the
timingwas unknown.We treated these events as if they
had occurred on the last day of follow-up for that par-
ticipant. Possible confounding by covariates was
assessed by repeating thesemodels including prespeci-
fied covariates likely to be associated with cardio-
vascular outcomes (age, sex, smoking status, presence
of diabetes, dyslipidaemia, and hypertension at base-
line, and history of coronary heart disease) where data
were available for more than 80% of participants. Pre-
specified subgroup analyses for dietary calcium, age,
sex, vitamin D status (serum 25-hydroxyvitamin D
≥50 nmol/l or <50 nmol/l), and supplement type
were done using interaction terms between treatment
allocation and the factor of interest.
We used Poisson regression models to assess the
relation between the total number of events and treat-
ment allocation. Because recurrent cardiovascular
events in an individual are unlikely to be independent,
we used Poisson regression with general estimating
equations to account for the intra-individual depen-
dence of events.
To assess statistical heterogeneity between summary
data at trial level we used Cochran’s Q statistic
(P<0.10) and the I2 statistic (I2>50%). No significant
statistical heterogeneity existed between trials in any
of the analyses. We used random effects models to
pool summary data at trial level. Publication bias was
assessed using Funnel plots and Egger’s regression
model.34 Analyses were done using SAS version 9.1
or Comprehensive Meta-analysis version 2 (Biostat,
Englewood, NJ). All tests were two tailed and we con-
sidered P<0.05 as significant.
RESULTS
Figure 1 shows the results of the literature search and
table 1 the characteristics of the eligible studies. The
quality of the five studies contributing patient level
data has been independently assessed in previous sys-
tematic reviews.3 35 36
All 11 eligible trials were double blind, randomised
studies. Themethodof randomisationwas stated expli-
citly in seven: one used a central randomisation service
and six used computer generated random numbers.
Allocation concealment was explicitly described in
four studies. Ten studies gave details of participants
who withdrew or were lost to follow-up. Compliance
was reported in all 11 studies, but the definitions for
compliance differed between studies and were not
always comparable. In general, studies reported com-
pliance ofmore than 75% in participants whowere tak-
ing tablets at study completion. Table 2 shows the
baseline cardiovascular characteristics, dietary cal-
cium intake, and vitamin D status of participants.
Table 1 | Characteristics of 15 studies eligible for inclusion in meta-analysis
Studies
No in calcium group/
No in control group
Daily dose
and supplement type
Trial duration
(years) Primary end point
Baseline mean
age (years) % female
Patient level data on cardiovascular outcomes:
Reid 199321 22 68/67 1 g lactogluconate-carbonate 4 Bone mineral density 58 100
Baron 199925 464/466 1.2 g carbonate 4 Colorectal adenoma 61 28
Grant 200528 2617/2675 1 g carbonate 4* Low trauma fracture 77 85
Reid 200615 16 732/739 1 g citrate 5 Clinical fracture 74 100
Reid 200833 216/107 0.6 g or 1.2 g citrate 2 Spinebonemineral density 56 0
Subtotal/average† 4097/4054 — 4.1 — 73 78
Trial level data on cardiovascular outcomes‡:
Dawson-Hughes 199019 238/123 0.5 g carbonate or citrate 2 Spinebonemineral density 58 100
Riggs 199824 119/117 1.6 g citrate 4 Bone mineral density 66 100
Bonithon-Kopp 200027 204/212 2 g lactogluconate-carbonate 3 Colorectal adenoma 59 37
Prince 200629 730/730 1.2 g carbonate 5 Osteoporotic fracture 75 100
Bonnick 200730 282/281 1 g carbonate 2 Spinebonemineral density 66 100
Lappe 200731 32 446/288 1.4 g citrate or 1.5 g carbonate 4 Fracture incidence 67 100
Subtotal/average† 2019/1751 — 3.8 — 68 93
Total/average† 6116/5805 4.0 72 83
No data on cardiovascular outcomes:
Smith 198918§ 84/85 1.5 g carbonate 4 Arm bone mineral density 51 100
Elders 199120 198/97 1gor 2g lactogluconate-carbonate
or citrate
2 Spinebonemineral density NA 100
Recker 199623 95/102 1.2 g carbonate 4 Vertebral fracture 74 100
Peacock 200026 126/135 0.75 g citrate 4 Hip bone mineral density 76 72
Subtotal/average† 503/419 — 4.0 — 69 88
NA=not available.
*All participants were followed for two years with a median follow-up of 45 months.
†Weighted by person years of follow-up.
‡Complete trial level data were available for two studies.29 31 Partially complete data were available for four studies19 24 27 30 (see table 2 for details).
§No original records remained but lead author recalled no heart attacks in either treatment group.
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Cardiovascular events by treatment allocation are
shown in table 3.
Patient level analysis
Table 4 shows the baseline characteristics of the treat-
ment groups in the five studies contributing patient
level data. The median (interquartile range) duration
of follow-up in both groups was 3.6 (2.7-4.3) years.
In total, 143 people allocated to calcium had a myo-
cardial infarction during follow-up compared with 111
allocated to placebo. The risk of incident myocardial
infarction in those allocated to calcium increased by
31% (hazard ratio 1.31, 95% confidence interval 1.02
to 1.67, P=0.035. fig 2). During follow-up, 167 people
allocated to calcium and 143 allocated to placebohad a
stroke (1.20, 0.96 to 1.50, P=0.11), 293 people allo-
cated to calcium and 254 allocated to placebo had
any of myocardial infarction, stroke, or sudden death
(1.18, 1.00 to 1.39, P=0.057), and 519 people allocated
to calcium and 487 allocated to placebo died (1.09,
0.96 to 1.23, P=0.18). The number needed to treat
(NNT)with calcium for five years to cause one incident
event was 69 for myocardial infarction, 100 for stroke,
61 for any of myocardial infarction, stroke, or sudden
death, and 77 for death.Adjusting for prespecified cov-
ariates related to cardiovascular outcomes with data
available for more than 80% of participants (age, sex,
smoking status, anddiabetes) did not change the results
of the primary analyses.
Prespecified subgroup analyses showed a significant
interaction between treatment allocation and dietary
calcium intake for myocardial infarction. Calcium
treatmentwas associatedwith an increased risk ofmyo-
cardial infarction in people with dietary calcium intake
above the median of 805 mg/day (hazard ratio 1.85,
95% confidence interval 1.28 to 2.67) but no increased
risk in those with dietary calcium intake below the
median (0.98, 0.69 to 1.38, P for interaction 0.01).
When the cohort was divided by fifths of dietary cal-
cium intake rounded to the nearest 100 mg/day, the
respective hazard ratios (95% confidence intervals)
for the effect of calcium treatment on myocardial
infarction were 1.18 (0.70 to 2.00) for <500 mg/day,
0.68 (0.39 to 1.18) for 500-699 mg/day, 2.28 (1.26 to
4.15) for 700-899 mg/day, 1.81 (0.97 to 3.41) for 900-
1099 mg/day, and 1.41 (0.81 to 2.48) for ≥1100 mg/
day; test for linear trend when hazard ratios are
expressed relative to the <500 mg/d fifth, P=0.12.
Interactions between treatment allocation and age,
sex, vitamin D status, or supplement type for myo-
cardial infarction were not significant, nor were they
between treatment allocation and any of these vari-
ables or dietary calcium intake for stroke, the compo-
site end point, or death.
Recurrent cardiovascular events tended to be more
common in people allocated to calcium. Comparing
people allocated to calciumwith those allocated to pla-
cebo, 19 versus 13 had more than one myocardial
infarction (P=0.38), 21 versus 13 had more than one
stroke (P=0.23), and 59 versus 32 had more than one
of myocardial infarction, stroke, or sudden death
(P=0.006). Poisson regressionmodels with general esti-
mating equations were used to estimate the effect of
calcium on the total number of events, including inci-
dent and recurrent events. Overall, 164 myocardial
infarctions occurred in people allocated to calcium
compared with 125 in those allocated to placebo (rela-
tive risk 1.32, 95% confidence interval 1.02 to 1.71,
P=0.032). Stroke occurred in 190 people allocated to
calcium compared with 156 allocated to placebo (1.24,
0.99 to 1.56, P=0.07). In total, 361 myocardial infarc-
tions, strokes, or sudden deaths occurred in people
allocated to calcium comparedwith 287 in people allo-
cated to calcium (1.27, 1.07 to 1.51, P=0.006).
Trial level analysis
Table 3 shows summary data on cardiovascular events
at trial level. Eight studies15 16 21 22 25 28-33 were included
in the main analysis. A further three trials19 24 27 had
data only available for subgroups of participants.
These three trials were included in a sensitivity analysis
that included data from all 11 trials. Publication bias
Table 2 | Baseline cardiovascular and other variables in trials with patient or trial level data available for cardiovascular outcomes. Values are means
(standard deviations) unless stated otherwise
Studies
Dietary calcium
(mg/day)
Vitamin D*
(nmol/l)
Weight
(kg)
Current smoker
(%)
Hypertension
(%)
Diabetes
(%)
Ischaemic heart
disease (%)
Lipid disorder
(%)
Dawson-Hughes19 406 (84) NA NA NA NA NA NA NA
Reid21 22 750 (290) 93 (37) 65 (9) 10 9 0 2 1
Riggs24 710 (290) 80 (25) NA NA NA NA NA NA
Baron25 880 (440) 73 (27) 82 (15) 19 37 10 12 32
Bonithon-Kopp27 980 (380) NA NA NA NA NA NA NA
Grant28 820 (350) 45 (18)† 65 (13) 12 NA 8 NA NA
Reid15 16 860 (390) 54 (18) 67 (11) 3 29 3 8 8
Prince29 915 NA 69 (13) NA NA NA NA NA
Bonnick30 1240 (580) NA NA 0.4 NA NA NA NA
Lappe31 32 1070 72 (20) 77 (15) NA NA NA NA NA
Reid33 870 (450) 92 (33) 83 (12) 3 8 0.3 0.3 4
NA=not available.
*25-hydroxyvitamin D.
†25-hydroxyvitamin D measured in sample of 80 participants.
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was not evident on inspection of Funnel plots or in
Egger’s regression model in any analysis (P>0.40 for
all analyses). Figure 3 shows the results of the main
analysis. Allocation to calcium supplements was asso-
ciated with an increased risk of myocardial infarction
(relative risk 1.27, 95% confidence interval 1.01 to
1.59, P=0.038) but not stroke, the composite end
point, or death. Including data from the three addi-
tional studies in the sensitivity analysis did not signifi-
cantly change the results for any end point.
DISCUSSION
In this pooled analysis of around 12 000 participants
from 11 randomised controlled trials, calcium supple-
ments were associatedwith about a 30% increase in the
incidence of myocardial infarction and smaller, non-
significant, increases in the risk of stroke andmortality.
When recurrent events in 10-17% of participants were
included in analyses, the results were similar, although
the relative risks tended to be slightly larger. The find-
ings were consistent across trials, with an increased
relative risk of myocardial infarction with calcium
observed in six of the seven trials in which at least
one event occurred, although no individual trial
reported a statistically significant effect. The risk of
myocardial infarction with calcium tended to be
greater in those with dietary calcium intake above the
median but was independent of age, sex, and type of
supplement.
Limitations of the review
Our study has some limitations. We excluded studies
that compared coadministered calcium and vitamin D
supplements with placebo. The results therefore may
not apply to coadministered calcium and vitamin D
supplements.Noneof the trials had cardiovascular out-
comes as the primary end points, and data on cardio-
vascular events were not gathered in a standardised
manner. In only two of the trials were the data adjudi-
cated by blinded trial investigators. However, unless
there was differential misclassification or misreporting
of cardiovascular events in people treated with cal-
cium, this is unlikely to alter the results, because the
data came from blinded, placebo controlled trials.
Incomplete or no data on cardiovascular outcomes
were available for seven trials in our analysis, compris-
ing about 15% of the total number of participants.
However, the small size of these trials and the consis-
tency of the findings in the other eight larger trials sug-
gest the missing data are unlikely to have substantially
changed the results.
Comparison with other studies
The current findings are consistent with trials of
patients with renal failure, in which calcium supple-
ments were associated with an increase in mortality.13
Few comparable data are available from observational
studies of calcium supplements. One study reported a
24% increase in coronary heart disease in Finnish post-
menopausal women using calcium supplements (with
or without vitamin D) compared with non-users.37
Non-fatal myocardial infarction in US men using cal-
cium supplements compared with non-users did not
increase significantly, although the relative risk for
each fifth of supplement intake ranged between 1.02
and 1.07.38
The relations between dietary calcium intake and
cardiovascular events have also been examined. The
inverse relation between calcium intake and
Table 3 | Number of people with cardiovascular events and deaths by treatment allocation
Studies
Calcium group Placebo group
No of
participants
Myocardial
infarction Stroke Composite* Death
No of
participants
Myocardial
infarction Stroke Composite* Death
Dawson-Hughes19† 238 0 0 NA NA 123 0 1 NA NA
Reid21 22 68 0 2 2 0 67 0 1 1 0
Riggs24‡ 119 0 0 0 1 117 0 0 0 0
Baron25 464 20 15 31 25 466 17 11 28 22
Bonithon-Kopp27§ 204 0 1 1 8 212 0 0 1 9
Grant28¶ 1311 45 56 97 238 1332 39 48 86 217
Grant28** 1306 44 60 100 220 1343 34 58 89 218
Reid15 16 732 31 34 60 34 739 21 25 50 29
Prince29†† 730 21 38 56 29 730 17 40 56 38
Bonnick30‡‡ 282 0 1 NA 2 281 0 2 NA 1
Lappe31 32†† 446 2 5 8 NA 288 2 4 8 NA
Reid33 216 3 0 3 2 107 0 0 0 1
Total 6116 166 212 358 559 5805 130 190 319 535
NA=not available.
*Any of myocardial infarction, stroke, or sudden death. Seventeen events were classified as sudden deaths that occurred in eight people allocated to calcium and nine allocated to placebo.
†Unpublished trial level data provided by author. Data on stroke available only for participants who withdrew from study.
‡Unpublished trial level data provided by author. Data available only for participants who withdrew from study.
§Unpublished trial level data provided by author. Data on cause of death only.
¶Calcium versus placebo arms in Randomised Evaluation of Calcium or Vitamin D (RECORD) study.
**Calcium and vitamin D versus placebo plus vitamin D arms in Randomised Evaluation of Calcium or Vitamin D (RECORD) study.
††Unpublished trial level data provided by author.
‡‡Unpublished trial level data provided by Boyd Scott.
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standardised mortality ratios for ischaemic heart dis-
ease in the United Kingdom was strong.6 In two US
prospective observational studies, women in the high-
est fourth of calcium intake had 30-40% lower cardio-
vascular mortality than those in the lowest fourth,7 and
those in the highest fifth of calcium intakehad a 30-40%
lower risk of ischaemic stroke than those in the lowest
fifth.8 No relation between calcium intake and ischae-
mic heart diseaseor strokewas observed in prospective
studies of US men,38 39 or of Dutch civil servants.40
Thus, in contrast with the observational and inter-
ventional studies of calcium supplements, these obser-
vational studies do not show increased cardiovascular
risks with higher dietary calcium intake. These differ-
ences suggest that cardiovascular risks from high cal-
cium intake might be restricted to use of calcium
supplements.
A body of evidence related to the current work
comes from studies comparing coadministered cal-
cium and vitamin D supplements with placebo,
which were excluded from our meta-analysis.
Recently, the Women’s Health Initiative reported
that calcium and vitamin D had no effect on the risk
of coronary heart disease or stroke.41 The findings of
that study might differ from ours for several reasons.
TheWomen’s Health Initiative used low dose vitamin
D supplements, and vitamin D deficiency has been
associated with increased risk of cardiovascular
disease42 and vitamin D supplementation with
decreased mortality.17 Also, the participants differed
from those in our meta-analysis: on average they
were younger (mean age 62 v 75 years), heavier
(mean weight 76 v 68 kg; 34% in Women’s Health
Initiative v 10% of women in our meta-analysis
weighed >80 kg), had higher calcium intakes (mean
1150 v 830 mg/day), and a higher proportion were
using hormone replacement therapy (52% v <3% in
our meta-analysis). Overall, 54% were taking non-
Table 4 | Baseline characteristics of participants in five studies included in patient level
analysis by treatment allocation. Values are percentages unless stated otherwise
Characteristics Calcium group Placebo group
Median (interquartile range) age (years) 74.5 (70-79) 74.6 (71-79)
Women 76.5 79.2
White ethnicity 97.2 97.7
Mean (SD) weight (kg) 68.4 (14.1) 67.9 (13.7)
Mean (SD) dietary calcium (mg/day) 837 (377) 831 (370)
Mean (SD) 25-hydroxyvitamin D (nmol/l)* 66.1 (28.9) 64.3 (27.5)
Current smoker 11.0 10.2
Hypertension† 28.0 28.4
Ischaemic heart disease† 8.1 7.8
Lipid disorder† 14.8 15.4
Diabetes 7.0 6.7
Proportion of women was significantly higher in placebo group because one study that only involved men had a
2:1 ratio of allocation to calcium or placebo.33 No other differences existed between groups. Medical conditions
at baseline were self reported by participants.
*Data available from four studies for 1445 participants in calcium groups and 1355 in placebo groups.
†Data available from four studies for 1480 participants in calcium groups and 1379 in placebo groups.
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death by treatment allocation in five studies that contributed patient level data
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protocol calcium supplements at baseline (30% were
taking ≥500 mg/day), increasing to 69% at the final
visit,43 44 compared with 1.2% taking non-protocol
calcium supplements at baseline in our meta-analysis.
In the subgroups of women in the Women’s Health
Initiative who most closely approximated the partici-
pants in our analyses (age 70-79 years, body mass
index <30 kg/m2, total calcium intake <800 mg/day),
the confidence intervals of the hazard ratios for coron-
ary heart disease with calcium and vitamin D included
the hazard ratio formyocardial infarctionweobserved.
It would be valuable to reanalyse the results of the
Women’s Health Initiative to assess the effects of cal-
cium and vitamin D in non-obese women and in
women not taking non-protocol calcium supplements.
Interestingly, the only study in our analysis that
reported a relative risk of less than 1.0 for myocardial
infarction with calcium also had high non-protocol use
of calcium supplements.31 32 45
The current analyses do not deal with the mechan-
isms bywhich calcium supplementsmight increase the
risk of myocardial infarction, but we have reviewed
this elsewhere.46 Calcium supplements acutely
increase serum calcium levels to a modest degree.47
Serum calcium levels have been positively associated
with an increased incidence ofmyocardial infarction in
large observational studies.48-50 Primary hyperpara-
thyroidism, a condition in which serum calcium levels
are raised, has also been associated with an increased
risk of cardiovascular events and death.51 52 Ingestion
of equivalent doses of calcium from dairy products has
a much smaller effect than calcium supplements on
serum calcium levels,53 which might account for the
absence of a detrimental vascular effect of dietary cal-
cium intake in the observational studies reviewed.Vas-
cular calcification is an established risk factor for
cardiovascular disease,54 and the process of vascular
calcification is similar to osteogenesis.55 Because cal-
cium supplements increase bone density it is possible
that they may also increase vascular calcification and
thereby cardiovascular events. In patients with renal
failure (both dialysis and predialysis populations) cal-
cium supplements accelerate vascular calcification and
increase mortality.12-14 Our graphical data are consis-
tent with the possibility that an increased risk of myo-
cardial infarction with calcium supplements emerges
quickly, pointing tomechanisms such as increased coa-
gulability or altered vascular flow, perhaps mediated
directly through the calcium sensing receptor or indir-
ectly through alterations in calcitropic hormones.
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  Prince 2006
  Reid 2006
  Lappe 2007
  Reid 2008
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Test for heterogeneity:
  I2=0% P=0.96
13
29
26
13
17
1
1
Study Relative risk of myocardial
infarction (95% CI)
Weight
(%)
  Baron 1999
  Grant 2005
  Grant 2005 Vit D
  Prince 2006
  Reid 2006
  Bonnick 2007
  Reid 2008
Total
Test for heterogeneity:
  I2=0% P=0.84
4
43
42
5
5
0.2
0.2
0.5 1.20.8 1 1.5 2 3
Study
Favours
calcium
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Relative risk of
death (95% CI)
Weight
(%)
Weight
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  Reid 1993
  Baron 1999
  Grant 2005
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Test for heterogeneity:
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1
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1
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Weight
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Test for heterogeneity:
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2
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1.12 (0.97 to 1.30)
1.12 (0.92 to 1.36)
1.07 (0.95 to 1.19)
P=0.038
P=0.13
P=0.25
P=0.26
Study Relative risk of myocardial infarction,
stroke, or sudden death (95% CI)
Fig 3 | Random effects models of effect of calcium supplementation on cardiovascular events and death. Full data were
available from these eight trials, but some trials do not appear in the figures because no events occurred during the trial: no
myocardial infarctions occurred in the study by Reid 19932122 or Bonnick 2007,30 no strokes occurred in the study by Reid
2008,33 and no deaths occurred in the study by Reid 1993.2122 Data on composite end point were not available for the study
by Bonnick 200730 or Lappe 2007.3132 Grant 2005 is a Randomised Evaluation of Calcium or Vitamin D (RECORD) study calcium
versus placebo arms, and Grant 2005 vitamin D is a RECORD study calcium plus vitamin D versus vitamin D plus placebo arms
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Calcium supplements modestly increase bone
density31533 and have marginal efficacy against
fracture.23 In a pooled analysis of studies contributing
patient level data,1521222528 33 the hazard ratio for frac-
ture was 0.90 (95% confidence interval 0.80 to 1.01)
and NNT for five years to prevent one fracture was 39.
A recent meta-analysis of the effect of calcium with or
without vitamin D on fracture reported a similar NNT
for five years of 48.3 Later meta-analyses reported that
combined supplementationwith calciumandvitaminD
reduced fractures, whereas vitamin D alone did not.5657
Incorporating the results from the current analysis of
studies contributing patient level data, treatment of
1000 people with calcium for five years would cause
an additional 14 myocardial infarctions, 10 strokes,
and 13 deaths, and prevent 26 fractures.
Conclusions
In summary, randomised studies suggest that calcium
supplements without coadministered vitamin D are
associated with an increased incidence of myocardial
infarction. The vascular effects of calcium supple-
ments, especially without vitaminD, should be studied
further. Although the magnitude of the increase in risk
is modest, the widespread use of calcium supplements
means that even a small increase in incidence of cardio-
vascular disease could translate into a large burden of
disease in the population. The likely adverse effect of
calcium supplements on cardiovascular events, taken
together with the possible adverse effect on incidence
of hip fracture258 and its modest overall efficacy in
reducing fracture (about 10% reduction in total
fractures)2 3 suggest that a reassessment of the role of
calcium supplements in the prevention and treatment
of osteoporosis is warranted.
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